At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Peginterferon alfa-2a +1 moredrug
Likely dose
Peginterferon alfa-2a 180 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Pilot, Open-Label, Monocenter, Efficacy and Safety Study Examining the Effects of Peginterferon Alfa-2a (Pegasys) With or Without Ribavirin (Copegus) in Patients With Chronic Hepatitis D
In Brief
A Phase 2 clinical trial evaluating Peginterferon alfa-2a and Ribavirin for Hepatitis D, Chronic. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis D, Chronic
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
Primary CompletionMay 2009
First PostedApr 2016
TodayJul 2026
First PostedApr 7, 2016
Enrollment StartSep 1, 2004
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.2 years ago
Interventions
Peginterferon alfa-2adrug
Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
Ribavirindrug
Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.